Multiple sclerosis: Possible immunological mechanisms
نویسندگان
چکیده
منابع مشابه
Immunological features in multiple sclerosis.
A clinical and laboratory profile of the immunological system of patients with multiple sclerosis (MS) strongly suggested that many specific immune deficiencies exist in MS. The immunological history showed that patients with MS had had more tonsillectomies, appendicectomies, and childhood infections than matched controls, which suggested that there had been problems in controlling various type...
متن کاملO9: Mechanisms and Therapeutic Options in Multiple Sclerosis
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system associated to myelin loss and neurodegeneration. Clinically patients suffer from diverse symptoms and face the risk to become wheelchair-bound. At the moment MS is incurable, thus there is an unmet need for therapeutic options.
متن کاملBiochemical and Immunological Markers of Multiple Sclerosis
Multiple sclerosis is the most common neurological disease in young adults characterized by recurrent relapses and/or progression within the central nervous system. It is a complex disease in which several pathophysiological mechanisms such as axonal/neuronal damage, demyelination, inflammation, gliosis, remyelination and repair, oxidative stres and excitotoxicity, alteration of the immune syst...
متن کاملNeurodegenerative Mechanisms of Multiple Sclerosis
In 80% of all MS cases, patients suffer from relapsingremitting (RR) MS, which have clearly defined periods of neurological deficits followed by (partial) recovery [1]. In those RRMS patients, 65% of the disease cases gradually evolves into secondary progressive (SP) MS, with progressive permanent neurological deficits. In 20% of all MS cases, patients have a progressive disease course from ons...
متن کاملGlatiramer acetate treatment of multiple sclerosis: an immunological perspective.
Glatiramer acetate (GA) has been used as an immunomodulatory agent for the treatment of relapsing-remitting multiple sclerosis (MS) in the United States since 1996. It is currently one of two first-line agents for use in the treatment of relapsing-remitting MS. GA was the first agent to be used in the treatment of MS that was developed using the animal model of MS called experimental autoimmune...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Immunology and Immunopathology
سال: 1989
ISSN: 0090-1229
DOI: 10.1016/0090-1229(89)90116-5